Leading diagnostics platform Redcliffe Lifetech said on Friday it has raised $61 million (approximately Rs 466 crore) in a funding round led by LeapFrog Investments. Healthquad, Schroders, LC Nueva, Growth Spark Ventures, and existing investors Chiratae Ventures and Alkemi Venture Partners participated in the round.

The company said that the investment would be used to expand its geographic coverage across the country, focusing on developing its low-cost, high-quality direct-to-consumer diagnostic services to second, third, and third Tier 3 and Tier 4 cities. The latest funding will also be used to expand its platform and increase its product offerings in radiology, disease data analysis and lifestyle management, further propelling it to shift India’s healthcare focus from treatment to early diagnosis and prevention. Mission.

Dheeraj Jain, the founder of Redcliffe, said: “Preventive medicine is the future of health in India, helping ordinary Indians get the information they need for health and well-being.” The company has established a one-stop diagnostics shop, offers an extensive range of testing options and provides care closer to the client. The new investment will help to rapidly scale to reach over 500 million Indians over the next five years target year, he added.

• Raymond Jumps 4% on Ex-BEL Chief’s Defence Appointment
• Supriya Lifescience Falls 12% on NDPS Act Proceedings
• Radico Hits Record High as Magic Moments Sales Soar 43%
• GK Energy Rallies on Rs 235.92 Crore Solar Pump Order
• Cupid Hits Fresh 52-Week High on Rs 128 Crore Block Deal

“Redcliffe’s vision of transforming healthcare from treating patients to promoting health will profoundly impact millions of people. We are delighted to be working with Dheeraj and his management team to expand their presence in India further,” said Investment Partner Biju Mohandas LeapFrog, Co-Head of Global Health Investments. Redcliffe currently has a network of 22 laboratories in 14 cities across the country.